Vistara™ Single-Gene NIPT
Vistara is the next evolution in NIPT, going beyond chromosomal conditions to single-gene disorders
Screened Conditions Include
- Noonan syndrome
- Osteogenesis imperfecta
- Rett syndrome
- And 21 other single-gene disorders across 30 genes
Conditions screened by Vistara have a combined incidence of 1 in 600 – higher than that of Down syndrome for pregnancies in women under 32.
No errors detected in clinical validation
Vistara’s clinical validation published in Nature Medicine showed the following performance metrics:2
- >99% sensitivity
- >99% specificity
Commercial experience has also shown no known false positives.4
Consider Vistara for:
Women who want to know as much as possible, non-invasively
Couples with male partner over 35 – 40-years-old (advanced paternal age)
Ultrasound anomalies including increased nuchal translucency and shortened long bones
Family history of hereditary conditions
Vistara can be a beneficial adjunct to traditional prenatal diagnostic procedures like chorionic villus sampling (CVS) and amniocentesis
- One of the most comprehensive Noonan panels available
- Screens for conditions not included in standard diagnostic microarray
- Findings on Vistara can be confirmed using the same original diagnostic sample, additional confirmatory procedures are not needed*
*Cells must be saved for additional diagnostic testing
1Snijders, et al. Ultrasound Obstet Gynecol 1999;13:167-170.
2Zhang J et al. Nat Med. 2019 Mar;25(3):439-447.
3Pagon RA et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
4Natera internal data on file.